Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Ver gráficos interactivos y estados completos →
| Cuenta de resultados | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-12-31 | 2018-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $7M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — | — | — |
| Beneficio bruto | — | $0M | $0M | $0M | ($1M) | ($1M) | ($1M) | $0M | — | — | — |
| % de margen bruto | — | — | — | — | — | — | — | — | — | — | — |
| Ingresos operativos (EBIT) | ($559M) | ($533M) | ($438M) | ($270M) | ($208M) | ($156M) | ($108M) | ($60M) | $0M | $0M | ($137M) |
| % de margen operativo | -7877.5% | — | — | — | — | — | — | — | — | — | — |
| Ingresos netos | ($538M) | ($506M) | ($414M) | ($259M) | ($211M) | ($157M) | ($107M) | ($66M) | $0M | $0M | ($137M) |
| % de margen neto | -7585.9% | — | — | — | — | — | — | — | — | — | — |
| EBITDA | ($539M) | ($505M) | ($413M) | ($259M) | ($198M) | ($157M) | ($108M) | ($66M) | $0M | — | — |
| Beneficio por acción (EPS) | $-2.81 | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 | $-1.22 | $-1.54 | $-0.00 | — | $-13.67 |
| Acciones en circulación (M) | 206M | 182M | 152M | 138M | 123M | 110M | 88M | 43M | 14M | — | 10M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de IMVT. /companies/us/IMVT
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms